| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J A Pospisilik, S G Stafford, H-U Demuth, R Brownsey, W Parkhouse, D T Finegood, C H S McIntosh, R A Pederso. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. vol 51. issue 4. 2002-05-10. PMID:11916911. |
the incretins, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1) are responsible for >50% of nutrient-stimulated insulin secretion. |
2002-05-10 |
2023-08-12 |
rat |
| Iskandar Idris, Divina Patiag, Samuel Gray, Richard Donnell. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochemical pharmacology. vol 63. issue 5. 2002-05-07. PMID:11911852. |
exendin-4 increases insulin sensitivity via a pi-3-kinase-dependent mechanism: contrasting effects of glp-1. |
2002-05-07 |
2023-08-12 |
Not clear |
| Iskandar Idris, Divina Patiag, Samuel Gray, Richard Donnell. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochemical pharmacology. vol 63. issue 5. 2002-05-07. PMID:11911852. |
the insulinotropic agent, exendin-4, is a long-acting analogue of glucagon-like peptide-1 (glp-1) which improves glucose tolerance in humans and animals with diabetes, but the underlying mechanisms and the effects of exendin-4 on peripheral (muscle/fat) insulin action are unclear. |
2002-05-07 |
2023-08-12 |
Not clear |
| Iskandar Idris, Divina Patiag, Samuel Gray, Richard Donnell. Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochemical pharmacology. vol 63. issue 5. 2002-05-07. PMID:11911852. |
a similar insulin-sensitizing effect was observed with exendin-4 in 3t3-adipocytes, but glp-1 had no effect on adipocyte insulin sensitivity. |
2002-05-07 |
2023-08-12 |
Not clear |
| J Cancelas, J A García-Martínez, M L Villanueva-Peñacarrillo, I Valverde, W J Malaiss. Resistance of succinic acid dimethyl ester insulinotropic action to exendin (9-39) amide. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 34. issue 1. 2002-04-30. PMID:11832995. |
since this was not the case, ex (9-39) could be safely used to abolish the incretin effect of glp-1 without interfering with the control of insulin secretion by circulating nutrients. |
2002-04-30 |
2023-08-12 |
rat |
| Asa Johansson, Tommy Olsson, Kristina Cederquist, Hakan Forsberg, Jens J Holst, Jonathan R Seckl, Bo Ahre. Abnormal release of incretins and cortisol after oral glucose in subjects with insulin-resistant myotonic dystrophy. European journal of endocrinology. vol 146. issue 3. 2002-04-23. PMID:11888847. |
although the incretins, gastric inhibitory polypeptide (gip) and glucagon-like peptide-1 (glp-1), as well as glucagon and cortisol, are known to influence islet function, the role of these hormones in conditions of insulin resistance and development of type 2 diabetes is unknown. |
2002-04-23 |
2023-08-12 |
human |
| Michael A Nauck, Markus M Heimesaat, Kai Behle, Jens J Holst, Markus S Nauck, Robert Ritzel, Michael Hüfner, Wolff H Schmiege. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of clinical endocrinology and metabolism. vol 87. issue 3. 2002-04-08. PMID:11889194. |
at insulin concentrations of approximately 45 mu/liter, glucose infusion rates were similar with and without glp-1 (p = 0.26). |
2002-04-08 |
2023-08-12 |
human |
| Michael A Nauck, Markus M Heimesaat, Kai Behle, Jens J Holst, Markus S Nauck, Robert Ritzel, Michael Hüfner, Wolff H Schmiege. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of clinical endocrinology and metabolism. vol 87. issue 3. 2002-04-08. PMID:11889194. |
glp-1 stimulated insulin secretion only at plasma glucose concentrations of at least 4.3 mmol/liter. |
2002-04-08 |
2023-08-12 |
human |
| Josephine M Egan, Astrid R Clocquet, Dariush Elah. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. The Journal of clinical endocrinology and metabolism. vol 87. issue 3. 2002-04-08. PMID:11889200. |
postprandial plasma glucose, insulin, and glp-1 did not rise in any subject, possibly because of delayed gastric emptying by exendin-4 even though its infusion had been terminated 4 h previously. |
2002-04-08 |
2023-08-12 |
human |
| M Tang-Christensen, N Vrang, P J Larse. Glucagon-like peptide containing pathways in the regulation of feeding behaviour. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. vol 25 Suppl 5. 2002-04-05. PMID:11840214. |
the pre-proglucagon derived peptides, glucagon-like peptide-1 (glp-1) and glucagon-like peptide-2 (glp-2) are both involved in a wide variety of peripheral functions, such as glucose homeostasis, gastric emptying, intestinal growth, insulin secretion as well as the regulation of food intake. |
2002-04-05 |
2023-08-12 |
rat |
| M L Villanueva-Peñacarrillo, J Puente, A Redondo, F Clemente, I Valverd. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine. vol 15. issue 2. 2002-04-04. PMID:11720253. |
in the type 2 diabetic model, glp-1, like insulin, stimulated in liver and fat only the glucotransporter translational process, while in the muscle an effect at the glut4 transcriptional level was also observed. |
2002-04-04 |
2023-08-12 |
rat |
| M L Villanueva-Peñacarrillo, J Puente, A Redondo, F Clemente, I Valverd. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine. vol 15. issue 2. 2002-04-04. PMID:11720253. |
in the type 1 diabetic model, glp-1 apparently exerted in the liver only a posttranslational effect on glut2 expression; in muscle and fat, while insulin was shown to have an action on glut4 at both transcriptional and translational levels, the effect of glp-1 was restricted to glucotransporter translation. |
2002-04-04 |
2023-08-12 |
rat |
| M L Villanueva-Peñacarrillo, J Puente, A Redondo, F Clemente, I Valverd. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine. vol 15. issue 2. 2002-04-04. PMID:11720253. |
in normal and diabetic rats, exogenous glp-1 controlled the glucotransporter expression in extrapancreatic tissues participating in the overall glucose homeostasis-liver, muscle, and fat-where the effect of the peptide seems to be exerted only at the translational and/or posttranslational level; in muscle and fat, the presence of insulin seems to be required for glp-1 to activate the transcriptional process. |
2002-04-04 |
2023-08-12 |
rat |
| TracyAnn Perry, Debomoy K Lahiri, Demao Chen, Jie Zhou, Karen T Y Shaw, Josephine M Egan, Nigel H Grei. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. The Journal of pharmacology and experimental therapeutics. vol 300. issue 3. 2002-03-28. PMID:11861804. |
the insulinotropic hormone glucagon-like peptide-1 (7-36)-amide (glp-1) has potent effects on glucose-dependent insulin secretion, insulin gene expression, and pancreatic islet cell formation and is presently in clinical trials as a therapy for type 2 diabetes mellitus. |
2002-03-28 |
2023-08-12 |
rat |
| Claus B Juhl, Malene Hollingdal, Jeppe Sturis, Grethe Jakobsen, Henrik Agersø, Johannes Veldhuis, Niels Pørksen, Ole Schmit. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. vol 51. issue 2. 2002-03-15. PMID:11812750. |
in conclusion, the long-acting glp-1 derivative nn2211 effectively reduces fasting as well as meal-related (approximately 12 h postadministration) glycemia by modifying insulin secretion, delaying gastric emptying, and suppressing prandial glucagon secretion. |
2002-03-15 |
2023-08-12 |
Not clear |
| Karen Moens, Veerle Berger, Jung-Mo Ahn, Chris Van Schravendijk, Victor J Hruby, Daniel Pipeleers, Frans Schui. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes. vol 51. issue 3. 2002-03-15. PMID:11872665. |
glucagon is a potent stimulator of insulin release in the presence of a permissive glucose concentration, activating beta-cells in vitro via both glucagon- and glucagon-like peptide-1 (glp-1)-receptors. |
2002-03-15 |
2023-08-12 |
rat |
| Karen Moens, Veerle Berger, Jung-Mo Ahn, Chris Van Schravendijk, Victor J Hruby, Daniel Pipeleers, Frans Schui. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes. vol 51. issue 3. 2002-03-15. PMID:11872665. |
in the perfused rat pancreas, neither of these antagonists inhibited the potent secretory response to 20 mmol/l glucose, although they effectively suppressed the potentiating effect of, respectively, an infusion of glucagon (1 nmol/l) or glp-1 (1 nmol/l) on insulin release. |
2002-03-15 |
2023-08-12 |
rat |
| Michael C Lawrence, Harshika S Bhatt, Richard A Easo. NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes. vol 51. issue 3. 2002-03-15. PMID:11872668. |
currently there is intense interest to define the mechanism of action of glucagon-like peptide-1 (glp-1) in regulating beta-cell function, including insulin gene transcription. |
2002-03-15 |
2023-08-12 |
rat |
| Michael C Lawrence, Harshika S Bhatt, Richard A Easo. NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes. vol 51. issue 3. 2002-03-15. PMID:11872668. |
in this study, glp-1 (100 nmol/l), in the presence of glucose (11 mmol/l), induced a similar71-fold increase in insulin gene promoter activity in ins-1 pancreatic beta-cells, an effect that was an order of magnitude larger than with either stimulant alone. |
2002-03-15 |
2023-08-12 |
rat |
| Michael C Lawrence, Harshika S Bhatt, Richard A Easo. NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes. vol 51. issue 3. 2002-03-15. PMID:11872668. |
furthermore, two-point base pair mutations in any of the three identified nfat sites within the rat insulin i promoter resulted in a significant reduction in the combined effect of glucose and glp-1. |
2002-03-15 |
2023-08-12 |
rat |